What is Cullgen?
Founded in 2018, Cullgen operates at the intersection of advanced molecular biology and pharmaceutical development. The company is dedicated to addressing diseases that currently lack effective therapeutic options through its specialized technology platform. By focusing on the science of protein degradation, Cullgen aims to modulate disease-causing proteins that were previously considered undruggable. This scientific focus has allowed the firm to transition from its initial Series A financing in 2019 to its current status as a major player in the biopharmaceutical sector, supported by a robust network of global investors and strategic partners.
How much funding has Cullgen raised?
Cullgen has raised a total of $106M across 3 funding rounds:
Series A
$16M
Series B
$50M
Series C
$40M
Series A (2019): $16M, investors not publicly disclosed
Series B (2021): $50M led by Octagon Capital, South China Venture Capital, Height Capital Management, 3E Bioventures Capital, and MSA Capital
Series C (2023): $40M supported by AstraZeneca, Wuxi Venture Capital Group, and GNI Group
Key Investors in Cullgen
AstraZeneca
AstraZeneca PLC is a global, science-led biopharmaceutical company focused on the discovery, development and commercialisation of prescription medicines across oncology, cardiovascular, and immunology sectors.
Wuxi Venture Capital Group
A government-backed investment institution based in Wuxi, focusing on providing financial support for high-tech startups and technology-driven enterprises.
GNI Group
A global healthcare company headquartered in Japan that leverages a unique drug discovery platform to create cost-effective solutions for unmet medical needs.
What's next for Cullgen?
With the recent capital injection, Cullgen is well-positioned to advance its lead candidates through critical stages of clinical development. The strategic focus will likely shift toward expanding its internal R&D capabilities and strengthening its intellectual property portfolio surrounding its proprietary degradation platform. As the company matures, the integration of global expertise from its investor base—ranging from multinational pharmaceutical giants to specialized life science venture firms—will be instrumental in navigating the regulatory landscape and scaling its operations to meet the urgent demand for novel, high-impact medical interventions.
See full Cullgen company page
